πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,828 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11993603

Preparation for 6-amino-1H-pyrazolo[3,4-d]pyrimidine-based JAK kinase inhibitor and applic

CHINA PHARMACEUTICAL UNIVERSITY Β· Granted Tue May 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11980633

Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitor

Vertex Pharmaceuticals Incorporated Β· Granted Tue May 14 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11969435

Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

Corcept Therapeutics Incorporated Β· Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11963959

Inhibitors for coronavirus

The Government of the United States, as represented by the Secretary of the Army Β· Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11964989

KRas G12D inhibitors

Mirati Therapeutics, Inc. Β· Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11964016

Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11963958

RET inhibitor for use in treating cancer having a RET alteration

Rigel Pharmaceuticals, Inc. Β· Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11957677

Cancer treatment using FGFR inhibitors and PLK1 inhibitors

Cardiff Oncology, Inc. Β· Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11958849

GLS1 inhibitors for treating disease

The Board of Regents of the University of Texas System Β· Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11957704

Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit be

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11952364

TRK inhibitors useful as anticancer drugs

TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED Β· Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11952376

Substituted amino acids as integrin inhibitors

Pliant Therapeutics, Inc. Β· Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11952366

Substituted 1,3,5-triazines as inhibitors for a rho family of GTP-ases

The Regents of the University of California Β· Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11951100

Formulations of RBP4 inhibitors and methods of use

Belite Bio, Inc Β· Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11952352

Ras inhibitors

Revolution Medicines, Inc. Β· Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11952389

Benzodiazepine derivatives as RSV inhibitors

Enanta Pharmaceuticals, Inc. Β· Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11944614

Imidazo[4,5-c]pyridine compounds as LSD-1 inhibitors

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11944626

Small molecule inhibitors of ALDH and uses thereof

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11945822

Pyrazolo-triazine and/or pyrazolo-pxrimidine derivatives as selective inhibitor of cyclin

Lead Discovery Center GmbH Β· Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11939361

Compositions of peptide inhibitors of Interleukin-23 receptor

Protagonist Therapeutics, Inc. Β· Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11939340

CDK inhibitors and their use as pharmaceuticals

Prelude Therapeutics, Incorporated Β· Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11938134

Metalloenzyme inhibitor compounds

Eikonizo Therapeutics, Inc. Β· Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11932692

Methods of treating cancer pain by administering a PD-1 inhibitor

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11931402

Compositions for treating heart disease by inhibiting the action of mAKAP-Ξ²

Anchored RSK3 Inhibitors, LLC Β· Granted Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted